GoodRx Holdings, Inc.

NASDAQ:GDRX

Medical - Healthcare Information Services

Healthcare
$3.36 +1.72%

+$0.05 today

Market cap
$1.15B
Beta
1.61
P/E (TTM)
44.0
EPS (TTM)
$0.06
52W Low $1.77High $5.81

Volume 0.66M

Average 1.61M

GDRX EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

GoodRx Holdings, Inc.NASDAQ: GDRX

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) declines year over year

Q1 FY2026 EPS (Basic) of $0 fell 88.7% year over year, behind the -42.7% change in trailing-twelve-month EPS (Basic). Sequentially, it fell 78.8% from the prior quarter.

Context

  • EPS (Basic) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 8 analysts of $0.29 (+244.1%) for the fiscal year ending Dec 2026, a step up from the +100.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-78.8% QoQ
Last fiscal yearDec 2025
$0.09+100.9% YoY
LTMMar 2026
$0.06-42.7% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-88.7%+121.3%+210.0 pp
1 year+100.9%+244.1%+143.2 pp
3-year CAGR—+63.9%—
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
0.09 USD
Year-over-year change
+100.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How GDRX compares with its peers on the latest reported figures

  • GDRX's LTM Mar 2026 EPS (Basic) of $0.06 is the highest of the 4 companies compared; the peer median is -$0.97.
  • Its year-over-year change of -42.7% is the lowest of 4, against a peer median of +46.8%.
GDRX Competitors Peer median
EPS (Basic) for GDRX and competitors
Company Period LTM YoY 3-year CAGR
GDRXGoodRx Holdings, Inc.LTM Mar 2026$0.06 -42.7%—
LFMDLifeMD, Inc.LTM Mar 2026-$0.41 -30.5%—
TDOCTeladoc Health, Inc.LTM Mar 2026-$0.97 +83.6%—
AMWLAmerican Well CorporationLTM Mar 2026-$5.42 +46.8%—
Peer median (excluding GDRX) -$0.97+46.8%—

Competitors are the stored peer set for GDRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue745.42M766.55M750.27M792.32M796.85M
Cost of Revenue46.72M65.08M66.93M48.22M57.6M
Gross Profit698.71M701.48M683.34M744.11M739.26M
Gross Margin93.7%91.5%91.1%93.9%92.8%
Research & Development125.86M143.14M135.84M123.75M121.03M
Selling, General & Admin524.9M502.42M466.84M484.98M445.52M
Operating Expenses685.3M699.74M710.35M678.26M651.76M
Depreciation & Amortization34.54M54.18M107.67M69.54M85.22M
EBITDA48M65.19M108.82M153.92M184.36M
EBITDA Margin6.4%8.5%14.5%19.4%23.1%
Operating Income13.41M1.74M(27.01M)65.85M87.49M
Operating Margin1.8%0.2%-3.6%8.3%11.0%
Interest Income59K9.27M32.17M23.27M10.93M
Interest Expense23.64M34.24M56.73M52.92M42.61M
Other Income / Expenses(23.58M)(24.97M)(28.57M)(34.39M)(30.95M)
Income Before Tax(10.18M)(23.23M)(55.57M)31.46M56.54M
Pre-Tax Margin-1.4%-3.0%-7.4%4.0%7.1%
Income Tax Expense15.08M9.6M(46.7M)15.07M26.1M
Net Income(25.25M)(32.83M)(8.87M)16.39M30.44M
Net Margin-3.4%-4.3%-1.2%2.1%3.8%
EPS (Basic)(0.06)(0.08)(0.02)0.040.09
EPS (Diluted)(0.06)(0.08)(0.02)0.040.09
Weighted Avg Shares409.98M412.86M410.32M385.74M356.33M
Weighted Avg Shares (Diluted)409.98M412.86M410.32M392.17M356.97M

GoodRx Holdings, Inc.

NASDAQ:GDRX

Intrinsic Alpha fair value

Locked

Current Price

$3.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.